ERBB2 and breast carcinoma: Lastly but most significantly, constructed biologic subtype was demonstrated to predict for OS; patients with non-Rec+/HER2- breast cancer had significantly worse 5-year OS despite the use of comprehensive locoregional and systemic therapies, which might be attributed to its aggressive nature.